Oncotarget
AUTHOR INSIGHT, COMMUNITY NEWS & EVENTS BY ONCOTARGET:
- Adjuvant PD-1/PD-L1 Inhibitors Show Efficacy but Highlight Safety Considerations in Solid Cancers
A new research paper was published in Volume 17 of Oncotarget on March 31, 2026, titled “Efficacy and safety of PD-1/ PD-L1 inhibitors as adjuvants in the treatment of patients with solid cancers: A systematic review and meta-analysis of randomized controlled trials.” - Bibliometric Mapping Reveals the Evolution of Glioma Classification Research
A new review was published in Volume 17 of Oncotarget on March 31, 2026, titled “Bibliometric mapping of glioma classification research through main path, key route, and K-core analyses.” - The SCD1 Inhibitor Aramchol, Regorafenib, and Metformin Combine to Kill Uveal Melanoma CellsA new research paper was published in Volume 17 of Oncotarget on March 27, 2026, titled “The SCD1 inhibitor aramchol interacts with regorafenib and metformin to kill tumor cells.”
ABOUT DR. MIKHAIL (MISHA) BLAGOSKLONNY:
It is with great sadness and heavy heart that we announce the recent passing of Dr. Mikhail (Misha) V. Blagosklonny, our beloved Editor-in-Chief. Misha succumbed to metastatic lung cancer after a courageous battle.
Dr. Blagosklonny will be remembered as a brilliant and extraordinary scientist who dedicated his life to science. He was a visionary thinker, who made highly original contributions to cancer and aging research that were often ahead of their time.
Dr. Blagosklonny was born into a family of scientists. His mother, Professor of Medicine Yanina V. Blagosklonnaya, specialized in endocrinology and was a talented teacher, mentoring several generations of medical students. His father, Professor Vladimir M. Dilman, was a brilliant gerontologist, endocrinologist and oncologist, known for being a very charismatic person. He was the first person to encourage Misha to think about nature, aging, and philosophy.
Misha was a theorist by nature. While in school, he was deeply interested in physics and dreamed of becoming a theoretical physicist. Eventually, he chose biology, driven to study aging and age-related diseases, including cancer. He started as an experimentalist, but over the years, he became a theoretical biologist. In a way, his dream came true.
Read the full tribute to Dr. Blagosklonny | @Blagosklonny
ABOUT ONCOTARGET.NET:
Oncotarget.net features press releases on the latest oncology research, as well as interviews from the distinguished network of authors who continue to publish their research with Oncotarget, an open access biomedical journal dedicated to publishing the latest oncology-focused, peer-reviewed research papers. Here, readers will also find information about community news and events sponsored by Oncotarget.
For the latest summaries of new and trending Oncotarget papers,visit Oncotarget.org or ImpactJournals.com. Impact Journals is Oncotarget’s academic publisher. Read about our rigorous Scientific Integrity Process.
CONTACT INFORMATION:
To get in touch with Oncotarget, please visit our website. The journal’s ISSN is 1949-2553 and is indexed and/or archived in PubMed, Scopus, PMC, and the Chan Zuckerberg Meta initiative.